BlackArch was retained by Avanti to serve as its exclusive financial advisor.
The transaction continues BlackArch’s significant momentum in the pharmaceutical services and healthcare sectors and is representative of the firm’s focus on providing dedicated M&A advisory services to market-leading businesses.
Avanti has agreed to be acquired by Croda International Plc. Avanti's know-how and technologies are highly complementary to Croda's capabilities in drug delivery systems, vaccine adjuvants and immunotherapy. Avanti will be able to combine its leading position in pharmaceutical lipid-based applications with Croda's access to global markets, greater manufacturing capacity and a broader set of capabilities to expand the range of products and services for the combined customer base.